Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam versus dexmedetomidine during scoliosis correction surgery
ChiCTR2300074834Phase 4Not yet recruiting
- Sponsor
- Shifang People's Hospital
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam and dexmedetomidine in scoliosis (3 arms), sponsored by Shifang People's Hospital. Primary endpoints: Intraoperative arousal quality and VAS scores. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
remimazolamdexmedetomidine
03
Conditions
scoliosis
Beyond the preview
Go deeper on ChiCTR2300074834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074834.